BIO-TECHNE Corp (TECH) Stock Price, Financials & Summary

Price chart

Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14

Key dataSep 14, 2026

Open$72.21

From 52W high−0.29%

Volume2.74M

Market cap$11.33B

P/E (TTM)61.8x

P/S (TTM)9.3x

Div yield0.44%

Key dataSep 14, 2026

Open

$72.21

From 52W high

−0.29%

Volume

2.74M

Market cap

$11.33B

ValuationView details →

P/E (Fwd)

35.2x

EV/EBITDA

33.1x

P/E (TTM)

61.8x

RSI (14)

58.3

MomentumView details →

1D Return

+0.21%

YTD Return

+22.82%

SummaryUpdated Jun 1, 2026

Bio-Techne Corporation (NASDAQ:TECH) is a Minneapolis-based biotechnology company founded in 1976 that develops, manufactures, and sells life science research tools and diagnostic products worldwide. Originally known as Techne Corporation until 2014, the company has grown through strategic acquisitions and organic expansion to become a leading provider of biological reagents, instruments, and services serving the research and clinical diagnostic markets. Bio-Techne operates through two primary business segments and has established itself as a critical supplier to pharmaceutical companies, biotechnology firms, academic institutions, and clinical laboratories globally.

Ask drillr about BIO-TECHNE Corp →

ValuationView details →

P/E (Fwd)

35.2x

P/E (TTM)

61.8x

EV/EBITDA

33.1x

EV/Sales

9.3x

P/S (TTM)

9.3x

P/B (TTM)

5.4x

ProfitabilityView details →

Gross Margin

65.77%

Net Margin

14.97%

EBITDA Margin

28.27%

ROE (TTM)

8.63%

ROA (TTM)

7.03%

Asset Turnover

0.47x

GrowthView details →

Revenue YoY

−0.38%

EPS YoY

+154.35%

FCF YoY

+2.60%

Revenue CAGR 3Y

+2.25%

EPS CAGR 3Y

−13.54%

EBITDA YoY

+58.36%

MomentumView details →

1D Return

+0.21%

YTD Return

+22.82%

1Y Return

+39.93%

RSI (14)

58.3

vs 50D SMA

+0.35%

vs 200D SMA

+17.81%

Capital & dividendView details →

Debt/Equity

0.14x

Current Ratio

4.55x

Quick Ratio

3.35x

Div Yield

0.44%

Div Rate

$0.32

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.52

EPS Surprise

0.19%

Beats (12Q)

6/12

Next Q EPS Est

$0.44

Avg Surprise (4Q)

0.80%

Rev Surprise

2.09%

Financials snapshotView financials →

Revenue (TTM)

1.22B

Net Income (TTM)

181.86M

Op. CF (TTM)

292.07M

Next earningsNov 4, 2026 →

Latest newsMore news →

BlackRock Inc. disclosed a new stake of 14,025,816 shares in Bio-Techne Corp, valued at approximately $990,924,000, representing about 8.96% ownership, in a recent SEC filing.24d ago

As of August 20, 2026, the total margin trading balance on China's A-share market decreased by 1.248 billion yuan to 2.666356 trillion yuan, with net financing purchases led by Zhongji Innolight at 530 million yuan.25d ago

Similar companies

Axsome Therapeutics, Inc.AXSM Nanjing Leads Biolabs Co Ltd09887.HK 欧林生物688319.SH Arrowhead Pharmaceuticals, Inc.ARWR Mabwell-b02493.HK Ascentage Pharma Group International06855.HK Find similar companies →

Latest newsMore news →

BlackRock Inc. disclosed a new stake of 14,025,816 shares in Bio-Techne Corp, valued at approximately $990,924,000, representing about 8.96% ownership, in a recent SEC filing.24d ago As of August 20, 2026, the total margin trading balance on China's A-share market decreased by 1.248 billion yuan to 2.666356 trillion yuan, with net financing purchases led by Zhongji Innolight at 530 million yuan.25d ago